Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calprotectin Involvement in Emergency Hematopoiesis Observed in Severe COVID-19
NCT04953312Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Trial (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Differential gene expression and epigenetic signature of COVID-19 or leukemic versus normal HSC at 12 months. Planned start Jan 2023; status: withdrawn.
Beyond the preview
Go deeper on NCT04953312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953312.